Immunity Insurance Coverage and Processing Magazine 
Pharmaceutical Technology
JULY 23, 2025
The legislation also supports the use of mobile manufacturing units, offering close-to-home treatment for patients too unwell to travel, or whose weakened immune systems mean hospital visits carry extra risk. Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.
Pharmaceutical Technology
AUGUST 14, 2025
Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva. The undisclosed biotech company’s option agreement with Apertura will investigate the potential of TfR1 CapX in conjunction with its payloads aimed at treating CNS disorders. The specific terms of the agreement remain confidential.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmaceutical Technology
JUNE 23, 2025
June 23, 2025 Share Copy Link Share on X Share on Linkedin Share on Facebook HBM7020 activates immune system T cells to target and destroy B cells and plasma cells involved in many autoimmune diseases. Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva. Credit: luchschenF /Shutterstock.
Pharmaceutical Technology
AUGUST 12, 2025
Sartorius Stedim Biotech has agreed to invest $3m in Nanotein Technologies, a US-based company engaged in the development of advanced immune cell activation reagents. However, developers encounter several challenges during this process, including dependence on feeder cells and variability in yields. Credit: New Africa/Shutterstock.com.
Pharmaceutical Technology
JUNE 20, 2025
Find out more This treatment involves obtaining immune cells from patients, modifying them in a laboratory setting then reintroducing them into patients’ bodies to destroy cancerous cells. Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva. Don’t let policy changes catch you off guard.
Pharmaceutical Technology
JULY 1, 2025
A preliminary look at the data from Capstan has revealed strong B-cell depletion – the aim of the treatment is to achieve an ‘immune reset’ by repopulation of healthy B cells. Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva. higher at $185.62 on 30 June, the day the announcement was made.
Pharmaceutical Technology
JULY 14, 2025
Robert Barrie July 14, 2025 Share Copy Link Share on X Share on Linkedin Share on Facebook Broader label coverages for Pfizer and Moderna’s vaccines mean they have made in-roads into GSK’s RSV dominant market share. MAXSHOT.PL via Shutterstock. FDA approvals do not automatically mean shots enter national immunisation schedules.
Expert insights. Personalized for you.
Let's personalize your content